Applications · in depth
What This Means for Medicine
More than half the drugs in use are chiral, and a chiral drug is really two drugs that happen to share a formula. This page works through why the body can tell them apart, what that costs, and exactly where Kagan's and Soai's results enter — which is not where most summaries put them.
The short version, stated up front so the rest can be read critically: Kagan's non-linear effects are in routine industrial use and save real money. Soai's autocatalysis is not used to make any medicine, and may never be. Both deserve the prize; only one of them is in your medicine cabinet.
1. Why a body can tell left from right
A receptor is a protein, built from L-amino acids and folded into a shape that is emphatically handed. When a drug binds, it makes contact at several points at once. A molecule and its mirror image can match at any two of those points — but not, in general, at three.
That is the whole mechanism, and it is worth stating because it explains the pattern of exceptions. Where binding is dominated by one or two contacts, or by bulk properties like lipophilicity, the two hands behave similarly. Where it depends on a precise three-dimensional fit, they can differ by orders of magnitude. The ratio of potencies has a name, the eudismic ratio, and it ranges from about 1 to well over 1000 depending on how much of the binding is geometric.
The active enantiomer is called the eutomer, the other the distomer. The distomer is not automatically a problem — it may be simply inert — but it is never automatically safe either, and that distinction took a disaster to establish.
2. Four separate ways the two hands can differ
These are independent, and conflating them is the commonest error in popular accounts.
- Pharmacodynamics — what the drug does to the body. One hand binds the target, the other may be inert, weaker, or an antagonist at the same receptor.
- Pharmacokinetics — what the body does to the drug. Metabolising enzymes are chiral too, so the two hands are absorbed, protein-bound, metabolised and cleared at different rates. This is the whole basis of the esomeprazole case below, and it has nothing to do with receptor binding.
- Toxicity — which may sit on either hand, and need not involve the therapeutic target at all.
- Chiral inversion — whether the body converts one hand into the other. This can be one-way or two-way, and it determines whether separating them achieves anything.
The fourth is the one that trips people up. If the hands interconvert faster than the drug acts, a single-enantiomer formulation is a racemate by the time it matters.
3. Four drugs, four different right answers
Thalidomide
(R) sedative · (S) teratogenicracemisation makes the question moot
The textbook example, and the one most often told wrongly. The two hands do differ: (R) sedates, (S) is teratogenic. But they interconvert in the body, with a racemisation half-life of roughly 12 hours in buffer and about one hour in serum. Administering pure (R) would have produced a racemic mixture inside the patient within hours. The tragedy was not a failure to separate enantiomers; it was a failure to test for teratogenicity at all.
Ibuprofen
(S) active · (R) inactive at COXsold as the racemate, correctly
Only (S)-ibuprofen inhibits cyclooxygenase. Yet the drug is sold racemic, and that is the right decision: (R)-ibuprofen undergoes unidirectional metabolic inversion to (S) in vivo, so the inactive half is effectively a prodrug for the active one. Purifying it would add cost and remove a reservoir. Note the contrast with thalidomide: ibuprofen inverts one way, thalidomide both ways, and the clinical conclusions are opposite.
Esomeprazole
(S)-omeprazolea genuine chiral switch
Omeprazole was marketed as the racemate; esomeprazole, approved in 2001, is the single (S) enantiomer. The pharmacodynamics are not the main story here, the pharmacokinetics are: the two enantiomers are cleared by CYP2C19 at different rates, so the single enantiomer gives higher and less variable exposure between patients. This is the archetype of the commercially motivated chiral switch, and arguments about how much clinical benefit it delivers have never entirely stopped.
Penicillamine
(D) therapeutic · (L) toxicsingle enantiomer, no alternative
Used as a chelator in Wilson’s disease. The L form antagonises pyridoxine and is toxic. Here there is no room for argument and no metabolic rescue: the drug must be made and sold as one hand.
Four chiral drugs; four different correct decisions. There is no general rule beyond “measure both hands and find out”, which is precisely what the regulators eventually mandated.
4. The rule that created an industry
On 27 May 1992 the FDA issued its policy statement on the development of stereoisomeric drugs. Its effect was to treat each enantiomer as a distinct chemical entity unless the applicant demonstrates otherwise — so a company proposing a racemate must characterise both hands: activity, pharmacokinetics, and toxicology, separately.
That single administrative decision is why asymmetric synthesis went from an elegant academic pursuit to a core industrial technology within a decade. It is also what made the economics of chiral catalysts matter, which is where this year's prize meets the pharmacy.
5. Where Kagan's result actually saves money
To make one hand at scale you need a chiral catalyst, and the handed ligand is usually the most expensive component in the process. Worse, the cost of a ligand is extremely non-linear in its purity: taking a ligand from 90% to 99% ee can mean repeated recrystallisation, with losses at every stage.
Now recall what Part 2 derived. With a sluggish meso complex, a ligand at 80% ee gives product at 97.6%; at 50% it still gives 80%. The purification steps that dominate the ligand cost can simply be omitted, because the reaction itself does the purifying.
This is not a marginal saving on a laboratory scale-up. Single-enantiomer drugs are made in tonnes, the catalyst is recycled imperfectly, and ligand cost is a line item that survives all the way to the price of the tablet.
The second industrial use is diagnostic rather than economic. Process chemists run the reaction at several ligand purities as a matter of routine: a straight line says the catalyst is monomeric and the mechanism is simple, a curve says it is not. That tells you whether a process will behave predictably on scale-up, which is worth knowing before you build the plant rather than after.
6. Why autocatalysis is not making your medicine
It would be convenient to claim the Soai reaction has pharmaceutical uses. It does not, and the reasons are instructive.
It works on one narrow class of substrate — the addition of dialkylzincs to particular pyrimidyl aldehydes — and nobody has generalised it. The products are not medicines and are not intermediates to medicines. And the very property that makes it remarkable makes it alarming to a process chemist: a reaction that amplifies any bias will amplify a contaminant you did not know about, and reproducibility is the one thing a regulated manufacturing process cannot compromise on.
Where the idea did reach the plant is adjacent and worth knowing about. Attrition-enhanced deracemisation — grinding a slurry of crystals so that one hand gradually consumes the other — relies on the same ingredients Frank identified: a self-amplifying process plus a mechanism that destroys the minority. It converts a racemate into a single enantiomer in the solid state, and it is used.
So the honest summary is that Soai's discovery proved a mechanism is real chemistry, and the mechanism now shows up in processes that look nothing like his reaction.
7. You still have to measure it
None of this works without an answer to a mundane question: what is the ee of this batch? A release specification for a single-enantiomer drug sets a limit on the unwanted hand, often below 0.1%, and that has to be demonstrated.
Optical rotation, the method Pasteur used, is far too insensitive. The workhorse is chromatography on a chiral stationary phase, which physically separates the two and measures the areas — one of the few analytical techniques whose entire operating principle is the same three-point discrimination that makes the receptor selective in the first place.
Sources for the clinical claims
FDA policy statement on the development of new stereoisomeric drugs, 27 May 1992. Thalidomide racemisation half-lives from studies of enantiomer interconversion in buffer and serum. Esomeprazole approved as a single enantiomer in 2001; the CYP2C19 clearance difference is the basis of its claimed advantage. Ibuprofen's unidirectional (R) → (S) inversion is long established in the 2-arylpropionic acid literature. Eudismic ratios vary widely and the figures quoted here are indicative.